Pathology AI Risk Stratification From Histology Features

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Conventional methods for estimating clinical metrics of cancer risk often overestimate or underestimate the risk of progression and/or recurrence, limiting effective treatment strategies.

Innovation Solution

A machine learning model, comprising a deep learning module and a multivariate model, is applied to histological samples to predict outcomes such as recurrence-free survival and treatment responses, using U-Net architecture for nuclei segmentation and classification, and Cox proportional hazards model for risk stratification.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional methods are used to estimate clinical metrics of cancer risk, then the estimation process is simple and quick, but the accuracy of risk prediction deteriorates (overestimation or underestimation of progression and recurrence risk)

Engineering Contradiction:
Improveaccuracy of risk predictionVSAvoidcomplexity of prediction system
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The prediction system is segmented into multiple specialized components: a deep learning module for extracting histological features from pathology slides, a feature engineering module for processing morphological and spatial data, and a multivariate model (Cox proportional hazards) for final risk prediction. This segmentation allows each component to specialize in specific tasks, improving overall prediction accuracy while managing complexity through modular architecture.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

A feature set acts as an intermediary between the raw histological data and the final risk prediction. The deep learning module extracts numerous histological features (nuclear morphology, tissue architecture, spatial relationships) which are then processed and fed into the multivariate model. This intermediary feature representation layer enables accurate risk prediction by transforming complex raw data into meaningful predictive variables.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If machine learning models are applied to pathology samples to improve prediction accuracy, then the accuracy of outcome prediction improves, but the complexity of the system increases

Engineering Contradiction:
Improvereliability of outcome predictionVSAvoidcomplexity of machine learning system
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The deep learning module performs preliminary action by pre-processing pathology images and extracting relevant histological features before the main prediction task. This preliminary feature extraction includes identifying nuclear morphology, tissue architecture, and spatial relationships, which prepares the data for more accurate subsequent risk prediction by the multivariate model.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The system incorporates feedback mechanisms where the multivariate model's predictions are continuously refined based on validated outcomes from patient follow-up data. The model parameters are adjusted through training on labeled datasets, creating a feedback loop that improves prediction reliability while managing system complexity through iterative optimization.

Inventive Principle:
Principle #23Feedback

Data Source

PatentUS20260018286A1Predicting patient outcomes related to cancer
Publication Date: 2026.01.15 VALAR LABS INC
  • US20260018286A1 patent drawing
  • US20260018286A1 patent drawing
  • US20260018286A1 patent drawing

AI summary

Disclosed are systems and methods for an artificial intelligence based pathology platform that can provide prognostic value to clinicians. For example, the platform can predict outcomes related to a cancer, and may include the steps of obtaining a histological sample of a cancer tumor of a patient, determining a feature set for the histological sample by applying a deep learning module trained on a population of histological samples of cancer tumors of the same type as the obtained histological sample of the cancer tumor, and generating an outcome set for the patient by applying a second model to the determined feature set.